Dysbiosis Clinical Trial
Official title:
Assessment of the Impact of Type of Probiotic, Delivery Type and Feeding Type on Baby's Microbiota After Dysbiotic Delivery
This study aims to determine the effect of three factors (delivery type, feeding type and the use of two different dietary supplements) on rebiosis after disbiotic delivery. This is a randomized, single-blinded study with two parallel arms. Group 1 will receive L. reuteri (10^8 CFU) once a day, group 2 will receive B. longum and P. Pentosaceus (10^9 CFU) once a day.
Gut colonization during the first days of life represents the start of the infant's own microbiota. This process is influenced by different factors: delivery type, feeding type, antibiotic treatment, etc. On the one hand, vaginally delivered babies are in contact with mother's vaginal and faecal microbiota. This fact will drive a neonatal gut colonization composed of vagina-associated bacteria. In contrast, babies born by C-section are more susceptible to be colonized by microorganisms present in the mother's skin. On the other hand, antibiotic administration during vaginal delivery also produces alterations in the vaginal microbiota of the mother. Described scenarios have been correlated to immunological and metabolic diseases such as asthma, allergies, diabetes or obesity. Moreover, disbiosis has also been associated to functional gastrointestinal disorders (FGID) in babies such as infant colic and functional constipation. After a disbiotic delivery, medical doctors usually recommend the use of probiotics to prevent rebiosis. Since the probiotics. L. reuteri, and B. longum and P. Pentosaceus have shown efficacy on FGID amelioration in previously published articles, these two probiotics were selected for the present study. All together, this study aims to characterize the role of three different parameters: type of probiotic, delivery type and feeding type. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05560087 -
Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
|
||
Recruiting |
NCT05288790 -
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
|
Phase 2 | |
Completed |
NCT06423586 -
Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
|
N/A | |
Completed |
NCT05575050 -
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
|
N/A | |
Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
Active, not recruiting |
NCT03554278 -
Alteration of Stool Microbiota in Preterm Infants With Anemia
|
||
Completed |
NCT03659240 -
Prebiotic Effects of a Polyphenol-rich Food Product
|
N/A | |
Completed |
NCT04118049 -
Vaginal Probiotics and Pessaries and Their Impact on the Vaginal Microenvironment
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Recruiting |
NCT04200521 -
The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
|
||
Completed |
NCT03523403 -
Obesity-related Health Benefits of Apples
|
N/A | |
Recruiting |
NCT05176535 -
Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)
|
N/A | |
Recruiting |
NCT06005298 -
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
|
N/A | |
Completed |
NCT03675048 -
Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section
|
N/A | |
Completed |
NCT03043300 -
A Pilot Study Assessing Intestinal Microbiota Diversification and Changes After Travel to South(East) Asia From the US
|
||
Recruiting |
NCT05790564 -
Almonds to Improve Gut Health and Decrease Inflammation
|
N/A | |
Completed |
NCT04561284 -
Carbohydrate-induced Resilience of the Gut Microbiome After Antibiotics Use
|
N/A | |
Enrolling by invitation |
NCT04527055 -
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
|
Phase 4 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Recruiting |
NCT05632497 -
Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa
|